Three critical advances in simplifying the adoption of P(V)-based stereopure, phosphorothioate-containing oligonu-cleotide synthesis are reported. A more inexpensive phosphorus-sulfur incorporation reagent (Ψ-Br) is introduced, a robust linker system was developed, and a systematic study of common nucleobase protecting groups performed to significantly reduce the barrier to adoption of this technology.
No takes yet. Share an insight, caveat, or question.
Nassir et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: